BioPharmSignal logoBioPharmSignal

Biotech News

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Context Therapeutics (CNTX)Context TherapeuticsClinical readout

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc.

Related news

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

CGEMCullinan Therapeutics, Inc.2026-09-10 17:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CGEMCullinan Therapeutics, Inc.2026-09-14 11:00 EST

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

ARGXArgenx2026-08-17 05:00 EST

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

View all latest news

Context Therapeutics

Solid-Tumor T-Cell Engagers Context Therapeutics develops bispecific antibodies that bind a tumor antigen and CD3 to recruit T cells against solid tumors. CTIM-76 CTIM-76 targets Claudin 6 and CD3. It is the company's lead Phase 1 program in tumors expressing the developmentally restricted CLDN6 antigen. CT-95 CT-95 is a...

Recent company news

CNTXContext Therapeutics2026-09-09 11:30 EST

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

CNTXContext Therapeutics2026-08-05 20:15 EST

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

CNTXContext Therapeutics2026-07-10 20:05 EST

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CNTXContext Therapeutics2026-07-06 20:07 EST

Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes

CNTXContext Therapeutics2026-06-15 10:30 EST

Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76

Stock data

Close
0.38 USD
Market cap
222.35M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States